New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

On behalf of our sponsors at Arcutis Biotherapeutics, we're learning more about Plaque Psoriasis, the chronic, inflammatory skin disease that affects many people and a new topical treatment that may ...

Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter.

From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss.

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research repo ...